Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

TitlePrecision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.
Publication TypeJournal Article
Year of Publication2015
AuthorsBuffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MRM, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG
JournalNature
Volume517
Issue7533
Pagination205-8
Date Published2015 Jan 08
ISSN1476-4687
KeywordsAnimals, Anti-Bacterial Agents, Bile Acids and Salts, Biological Evolution, Clostridium, Clostridium difficile, Colitis, Disease Susceptibility, Feces, Female, Humans, Intestines, Metagenome, Mice, Mice, Inbred C57BL, Microbiota, Symbiosis
Abstract

The gastrointestinal tracts of mammals are colonized by hundreds of microbial species that contribute to health, including colonization resistance against intestinal pathogens. Many antibiotics destroy intestinal microbial communities and increase susceptibility to intestinal pathogens. Among these, Clostridium difficile, a major cause of antibiotic-induced diarrhoea, greatly increases morbidity and mortality in hospitalized patients. Which intestinal bacteria provide resistance to C. difficile infection and their in vivo inhibitory mechanisms remain unclear. Here we correlate loss of specific bacterial taxa with development of infection, by treating mice with different antibiotics that result in distinct microbiota changes and lead to varied susceptibility to C. difficile. Mathematical modelling augmented by analyses of the microbiota of hospitalized patients identifies resistance-associated bacteria common to mice and humans. Using these platforms, we determine that Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium, is associated with resistance to C. difficile infection and, upon administration, enhances resistance to infection in a secondary bile acid dependent fashion. Using a workflow involving mouse models, clinical studies, metagenomic analyses, and mathematical modelling, we identify a probiotic candidate that corrects a clinically relevant microbiome deficiency. These findings have implications for the rational design of targeted antimicrobials as well as microbiome-based diagnostics and therapeutics for individuals at risk of C. difficile infection.

DOI10.1038/nature13828
Alternate JournalNature
PubMed ID25337874
PubMed Central IDPMC4354891
Grant ListU54 CA148967 / CA / NCI NIH HHS / United States
DP2OD008440 / OD / NIH HHS / United States
P01 CA023766 / CA / NCI NIH HHS / United States
T32GM07739 / GM / NIGMS NIH HHS / United States
K23 AI095398 / AI / NIAID NIH HHS / United States
T32 CA009149 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
AI95706 / AI / NIAID NIH HHS / United States
R01 AI095706 / AI / NIAID NIH HHS / United States
R01 AI42135 / AI / NIAID NIH HHS / United States
DP2 OD008440 / OD / NIH HHS / United States
R37 AI039031 / AI / NIAID NIH HHS / United States
R01 AI042135 / AI / NIAID NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States

Person Type: